Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 16/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | MAP2K2 | P36507 | 4/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.36 |
| ▸ | CSF1R | P07333 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24195794 | 0.89 | MAP2K1 (0.51) | MAP2K1KDRMAP2K2CSF1RHDAC3 | |
| SCHEMBL24195909 | 0.89 | MAP2K1 (0.50) | MAP2K1MAP2K2MAP2K5 | |
| SCHEMBL24195670 | 0.88 | MAP2K1 (0.46) | MAP2K1MAP2K2MAP2K5 | |
| SCHEMBL24195907 | 0.87 | MAP2K1 (0.40) | MAP2K1MAP2K2CSF1RHDAC3HDAC1 | |
| SCHEMBL26046827 | 0.87 | MAP2K1 (0.42) | MAP2K1KDRMAPK1MAP2K2BRAF | |
| SCHEMBL24195776 | 0.87 | MAP2K1 (0.40) | MAP2K1MAP2K2CSF1RHDAC3HDAC1 | |
| SCHEMBL24196118 | 0.86 | MAP2K1 (0.52) | MAP2K1KDRMAP2K2 | |
| SCHEMBL24196126 | 0.85 | MAP2K1 (0.42) | MAP2K1MAP2K2MAP2K5CSF1RHDAC3 | |
| SCHEMBL24196127 | 0.85 | MAP2K1 (0.43) | MAP2K1MAP2K2HDAC3HDAC1HDAC6 | |
| SCHEMBL24196109 | 0.84 | HDAC1 (0.39) | MAP2K1KDRMAP2K2CSF1RHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4233865-A2 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | NFlection Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |